Kensaku Takanashi
Tohoku University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kensaku Takanashi.
Scientific Reports | 2017
Kohsuke Gonda; Mika Watanabe; Hiroshi Tada; Minoru Miyashita; Yayoi Takahashi-Aoyama; Takashi Kamei; Takanori Ishida; Shin Usami; Hisashi Hirakawa; Yoichiro Kakugawa; Yohei Hamanaka; Ryuichi Yoshida; Akihiko Furuta; Hisatake Okada; Hideki Goda; Hiroshi Negishi; Kensaku Takanashi; Masaru Takahashi; Yuichi Ozaki; Yuka Yoshihara; Yasushi Nakano; Noriaki Ohuchi
The quantitative sensitivity and dynamic range of conventional immunohistochemistry (IHC) with 3,3′-diaminobenzidine (IHC-DAB) used in pathological diagnosis in hospitals are poor, because enzyme activity can affect the IHC-DAB chromogenic reaction. Although fluorescent IHC can effectively increase the quantitative sensitivity of conventional IHC, tissue autofluorescence interferes with the sensitivity. Here, we created new fluorescent nanoparticles called phosphor-integrated dots (PIDs). PIDs have 100-fold greater brightness and a more than 300-fold greater dynamic range than those of commercially available fluorescent nanoparticles, quantum dots, whose fluorescence intensity is comparable to tissue autofluorescence. Additionally, a newly developed image-processing method enabled the calculation of the PID particle number in the obtained image. To quantify the sensitivity of IHC using PIDs (IHC-PIDs), the IHC-PIDs method was compared with fluorescence-activated cell sorting (FACS), a method well suited for evaluating total protein amount, and the two values exhibited strong correlation (R = 0.94). We next applied IHC-PIDs to categorize the response to molecular target-based drug therapy in breast cancer patients. The results suggested that the PID particle number estimated by IHC-PIDs of breast cancer tissues obtained from biopsy before chemotherapy can provide a score for predicting the therapeutic effect of the human epidermal growth factor receptor 2-targeted drug trastuzumab.
Archive | 2012
Kensaku Takanashi; Hisatake Okada; Yasushi Nakano; Kohsuke Gonda; Noriaki Ohuchi; Mika Watanabe
Archive | 2013
Hideki Hoshino; 星野 秀樹; Hideki Gouda; 秀樹 郷田; Kensaku Takanashi; 健作 高梨; Yasushi Nakano; 中野 寧; Kohsuke Gonda; 幸祐 権田; Noriaki Ohuchi; 憲明 大内; Mika Watanabe; みか 渡邉
Archive | 2014
Hideki Gouda; 秀樹 郷田; Masaru Takahashi; 高橋 優; Kensaku Takanashi; 健作 高梨; Fuminori Okada; 文徳 岡田
Archive | 2014
Kensaku Takanashi; Yasushi Nakano; Takeshi Isoda; Hideki Gouda
Archive | 2013
Kensaku Takanashi; Hideki Gouda; Keizou Takano; Hideki Hoshino; Yasushi Nakano; Kohsuke Gonda; Noriaki Ohuchi; Mika Watanabe
Archive | 2011
Masaru Takahashi; Kensaku Takanashi; Hideki Hoshino; Kohsuke Gonda; Motohiro Takeda; Noriaki Ohuchi
Archive | 2014
Masaru Takahashi; Kensaku Takanashi
Archive | 2018
Kensaku Takanashi; Hideki Goda; Hisatake Okada; Yasushi Nakano; Kohsuke Gonda; Motohiro Takeda; Noriaki Ohuchi
Archive | 2018
Hideki Gouda; Kensaku Takanashi; Kohsuke Gonda; Noriaki Ohuchi; Mika Watanabe